{
    "clinical_study": {
        "@rank": "73812", 
        "arm_group": {
            "arm_group_label": "Bortezomib", 
            "arm_group_type": "Experimental", 
            "description": "Bortezomib will be administered by subcutaneous injection twice weekly for 2 weeks (Days 1, 4, 8, and 11) at 1.3 mg/m2/dose followed by a 10-day rest period for a 21 day cycle. Dose modifications are permitted as per a prescribed algorithm. Acyclovir at 400mg daily is recommended as prophylaxis for herpes zoster. Restaging scans, with evaluation of response, will be done every 2 cycles (6 weeks of treatment \u00b1 7 days). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 2 weeks, or at the discretion of the treating physician or patient."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the drug Bortezomib to see how well it works. The\n      investigators want to find out what effects, good or bad, it has on patients with a limited\n      smoking history or who have a specific mutation associated with their lung cancer."
        }, 
        "brief_title": "Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologic or cytologic evidence of non-small cell lung cancer (NSCLC)\n\n          -  Documented KRAS mutation\n\n          -  History of smoking < 100 cigarettes (never-smoker) OR patient with a KRAS G12D\n             mutation regardless of smoking history\n\n          -  Clinical stage IIIB/IV or recurrent/medically inoperable NSCLC\n\n          -  Age \u2265 18 years\n\n          -  Three (3) weeks since last chemotherapy, and three (3) weeks since prior radiation\n             therapy and recovered from treatment\n\n          -  Karnofsky performance status \u2265 70%\n\n          -  Adequate hematologic, and/or hepatic function WBC \u2265 3,000/ul or absolute neutrophil\n             count \u2265 1,000/ul Hemoglobin \u2265 9.0 g/dl Platelet count \u2265 100,000/ul AST \u2264 2.0 X ULN\n             (upper limit of normal)\n\n          -  Total bilirubin \u22641.5 x ULN Measurable indicator lesions by RECIST v1.1 criteria.\n\n          -  Voluntary written informed consent before performance of any study-related procedure\n             not part of normal medical care, with the understanding that consent may be withdrawn\n             by the subject at any time without prejudice to future medical care.\n\n          -  Female subject is either postmenopausal for at least 1 year before the screening\n             visit, is surgically sterilized or if they are of childbearing potential, agree to\n             practice 2 effective methods of contraception from the time of signing the informed\n             consent form through 30 days after the last dose of bortezomib, or agree to\n             completely abstain from heterosexual intercourse.\n\n          -  Male subjects must agree to 1 of the following: practice effective barrier\n             contraception during the entire study treatment period and through a minimum of 30\n             days after the last dose of study drug, or completely abstain from heterosexual\n             intercourse.\n\n        Exclusion Criteria:\n\n          -  Uncontrolled central nervous system metastases defined as any lesion which is either\n             a. symptomatic, or requiring escalating doses of corticosteroids\n\n          -  Significant medical history or unstable medical condition such as uncontrolled\n             diabetes myocardial infarction within 6 months prior to enrollment New York Heart\n             Association Class III or IV heart failure severe uncontrolled ventricular arrythmias\n             uncontrolled angina ECG evidence of acute ischemia or active conduction system\n             abnormalities\n\n          -  Baseline \u2265 grade 2 peripheral neuropathy by CTCAE v 4.0 (Appendix B)\n\n          -  Known hypersensitivity to boron or mannitol\n\n          -  Female patients who are pregnant/lactating or have a positive serum or urine \u03b2-hCG\n             pregnancy test\n\n          -  Serious medical or psychiatric illness likely to interfere with participation in this\n             clinical study.\n\n          -  No active concurrent malignancy, with the exception of in-situ malignancy completely\n             resected basal cell carcinoma or squamous cell carcinomas of the skin low-risk\n             prostate cancer after curative therapy\n\n          -  Participation in clinical trials with other investigational agents not included in\n             this trial, within 14 days of the start of this trial and throughout the duration of\n             this trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01833143", 
            "org_study_id": "12-222"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bortezomib", 
                "intervention_name": "Bortezomib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Bortezomib", 
                "intervention_name": "Acyclovir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acyclovir", 
                "Bortezomib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "KRAS-Mutant", 
            "Bortezomib", 
            "KRAS G12D", 
            "12-222"
        ], 
        "lastchanged_date": "February 10, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Gregory Riely, MD, PhD", 
                    "phone": "646-888-4202"
                }, 
                "facility": {
                    "address": {
                        "city": "Basking Ridge", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Memoral Sloan Kettering Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gregory Riely, MD, PhD", 
                    "phone": "646-888-4202"
                }, 
                "facility": {
                    "address": {
                        "city": "Commack", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11725"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center @ Suffolk"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gregory J Riely, MD"
                }, 
                "contact_backup": {
                    "last_name": "Paul Paik, MD", 
                    "phone": "646-888-4202"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Gregory J Riely, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gregory Riely, MD, PhD", 
                    "phone": "646-888-4202"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockville Centre", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11570"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Mercy Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gregory Riely, MD, PhD", 
                    "phone": "646-888-4202"
                }, 
                "facility": {
                    "address": {
                        "city": "Sleepy Hollow", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10591"
                    }, 
                    "name": "Memoral Sloan Kettering Cancer Center at Phelps"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Trial of Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D", 
        "overall_contact": {
            "last_name": "Gregory Riely, MD PhD", 
            "phone": "646-888-4199"
        }, 
        "overall_contact_backup": {
            "last_name": "Paul Paik, MD", 
            "phone": "646-888-4202"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Gregory Riely, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The following evaluations will be conducted to assess the efficacy of bortezomib - radiographic response rate by RECIST v1.1", 
            "measure": "efficacy of single-agent subcutaneous bortezomib", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01833143"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary endpoints of progression free survival, 8-week stable disease, and overall survival will be evaluated according to RECIST v.1.1 criteria as well.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Before each drug dose, the patient will be evaluated for possible toxicities that may have occurred after the previous dose(s). Toxicities are to be assessed according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE v4.0,).", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}